ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1282 • ACR Convergence 2023

    Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement

    Meliha Kapetanovic1, Olivia Olsson2, Jon Einarsson1, Morteza Najibi3 and Ellen Tufvesson4, 1Lund University and Skåne University Hospital, Lund, Sweden, 2Lund University, Faculty of Medicine, Lund, Sweden, 3Lund University, Institution for clinical sciences, section for rheumatology Lund, Lund, Sweden, 4Lund University, Institution for clinical scienses, section for lung medicine and allergy, Lund, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) related lung manifestations have a significantly impact the morbidity and mortality. Male gender and RF/ACPA positivity are known risk factors but…
  • Abstract Number: 1298 • ACR Convergence 2023

    Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice

    Fiona Oudart1, Marion THOMAS2, Alice Combier3, Anna Molto2, Yannick ALLANORE4 and Jérôme Avouac5, 1Université Paris Cité, Paris, France, 2HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 3APHP / Cochin Hospital, Paris, France, 4Université Paris Cité, Paris, France, 5Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France

    Background/Purpose: Increased risk of venous thromboembolism (VTE) has been reported in rheumatoid arthritis (RA) compared to the general population. However, factors associated with the risk…
  • Abstract Number: 1314 • ACR Convergence 2023

    Safety Results from a Phase 1 Double-blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early RA

    Nora Singer1, Maya Breitman2, Maricela Haghiac2, Larraine Gordesky3, Jane Reese4, Steven Lewis2, Emma Barnboym2, Noor Hussein5, Susan Lasalvia6, Elizabeth Mellins7, Tracey Bonfield8, Donald Anthony9, Arnold Caplan10 and Hillard Lazarus8, 1The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, 2The MetroHealth System at CWRU, Cleveland, OH, 3The MetroHealth System at CWRU and Louis Stokes Cleveland VA, Cleveland, OH, 4CWRU, University Hospitals of Cleveland, Cleveland, OH, 5Stanford University, Palo Alta, CA, 6The MetroHealth System, Cleveland, OH, 7Stanford University, Stanford, CA, 8CWRU and University Hospitals of Cleveland, Cleveland, OH, 9Case Western Reserve University, Cleveland VA Medical Center, The MetroHealth System, Cleveland, OH, 10CWRU, Center for Skeletal Biology, Cleveland, OH

    Background/Purpose: The purpose of this study was to evaluate the safety of bone-marrow derived allogeneic mesenchymal stem cells (MSCs) as therapeutic agents in early rheumatoid…
  • Abstract Number: 1331 • ACR Convergence 2023

    Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial

    Carlijn Wagenaar1, Wendy Walrabenstein1, Marike Van der Leeden2, Franktien Turkstra2, Jos W.R. Twisk1, Maarten Boers1, Henriët van Middendorp3, Peter Weijs4 and Dirkjan van Schaardenburg5, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Reade Rheumatology Center, Amsterdam, Netherlands, 3Leiden University, Leiden, Netherlands, 4Amsterdam University of Applied Sciences, Amsterdam, Netherlands, 5Reade, Amsterdam, Netherlands

    Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
  • Abstract Number: 1349 • ACR Convergence 2023

    Paternal Effects of Anti-TNFs in Inflammatory Arthritis

    Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
  • Abstract Number: 1677 • ACR Convergence 2023

    Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial

    Abhishek Abhishek1, Nicholas Peckham2, Corinna Pade3, Joseph Gibbons3, Lucy Cureton2, Anne Francis2, Vicki Barber2, Jennifer Williams2, duncan Appelbe2, lucy Eldridge2, patrick Julier2, daniel Altmann4, James Bluett5, Tim Brooks6, Laura Coates2, ines Rombach7, Amanda Semper6, Ashley Otter6, Ana Valdes1, Jonathan Nguyen-Van-Tam1, Hywel Williams1, Aine McKnight3, Rosemary Boyton4 and jonathan Cook2, 1University of Nottingham, Nottingham, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3Queen Mary University of London, London, United Kingdom, 4Imperial College London, London, United Kingdom, 5University of Manchester, Manchester, United Kingdom, 6UK Health Security Agency, Porton Down, United Kingdom, 7University of Sheffield, Sheffield, United Kingdom

    Background/Purpose: Immunosuppressive treatments inhibit vaccine-induced immunity. We evaluated if a two-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein…
  • Abstract Number: 1732 • ACR Convergence 2023

    Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA)

    Huiyi Wang1, Kangkang Luo1, Shuxin Xu1, Jiayin Zhou1, Santi Chen2, Jun wang2, Wenzhao Li2, Jing Zhao1 and Cunxiang Ju1, 1GemPharmatech CO., Ltd., Nanjing, China, 2GemPharmatech LLC, La Jolla, CA

    Background/Purpose: The differences between human and mouse immune systems make it challenging to accurately reflect the immunopathogenesis of autoimmune diseases in patients. Therefore, translational research…
  • Abstract Number: 1748 • ACR Convergence 2023

    Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies

    S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
  • Abstract Number: 1764 • ACR Convergence 2023

    Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease

    Breanna Butler1, Jill Poole1, Michael Duryee1, Nozima Aripova1, Carlos Hunter1, Bridget Kramer1, James O'Dell1, Geoffrey Thiele1, Bryant England1 and Ted R Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
  • Abstract Number: 1850 • ACR Convergence 2023

    Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data

    Andriko Palmowski1, Eric Roberts2, Jing Li2, Emma Kersey2, Rachael Stovall2, Frank Buttgereit3, Jinoos Yazdany4 and Gabriela Schmajuk5, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2University of California San Francisco, San Francisco, CA, 3Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, 4University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 5UCSF / SFVA, San Francisco, CA

    Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…
  • Abstract Number: 1912 • ACR Convergence 2023

    Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System

    Khashayar Ahmadmehrabi1, Navin Ravishankar2, Diana Mekhiel3 and Zineb Aouhab3, 1Loyola University Medical Center, Oak Park, IL, 2Indiana University Health, Indianapolis, IN, 3Loyola University Medical Center, Maywood, IL

    Background/Purpose: Given the progressive joint damage and physical disability associated with uncontrolled Rheumatoid arthritis (RA), a treat-to target-strategy through the early utilization of disease-modifying antirheumatic…
  • Abstract Number: 2101 • ACR Convergence 2023

    Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method

    Yusuke Miwa1, Yuko Miwa-mitamura2, Hiroi Tomioka3 and Michio Hosaka4, 1Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, 2Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Tokyo, Japan, 3Department of Psychiatry, School of Medicine, Showa University, Yokohama, Japan, 4Department of psychosomatic medicine, Katsuyama Clinic, Fujikawaguchiko, Japan

    Background/Purpose: It has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods.…
  • Abstract Number: 2118 • ACR Convergence 2023

    New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry

    Robert Spandorfer1, Kevin Kane2, George Reed2, Dimitrios Pappas2, Joel Kremer2, Jeffrey Curtis3 and Iris Navarro-Millán4, 1Hospital for Special Surgery, Brooklyn, NY, 2CorEvitas, LLC, Waltham, MA, 3University of Alabama at Birmingham, Birmingham, AL, 4Weill Cornell Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
  • Abstract Number: 2134 • ACR Convergence 2023

    Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA

    Monica Leu Agelii1, Outi Sareila2, Erik Lönnblom2, Kristina Forslind3, Maria Andersson3, Alf Kastbom4, Christopher Sjöwall5, Lennart Jacobsson6, Jan Kihlberg7, Rikard Holmdahl2, Ingiäld Hafström2 and Inger Gjertsson8, 1Gothenburg University, Goteborg, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3FoU Spenshult, Halmstad, Sweden, 4Linköping University, Linköping, Sweden, 5Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 6University of Gothenburg, Malmö, Sweden, 7Uppsala University, Uppsala, Sweden, 8Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: One of the major challenges in the management of rheumatoid arthritis (RA) is to determine individual treatment and predict the prognosis. On a group…
  • Abstract Number: 2150 • ACR Convergence 2023

    Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients

    Yuriko Yamamura1, Valerie Corrigall2, Lara Ravanetti3, Jorge De Alba3, Roly Foulkes4, Paul Eggleton5 and Carl Goodyear6, 1School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, 2Revolo Biotherapeutics, Tadworth, United Kingdom, 3Revolo Biotherapeutics, London, United Kingdom, 4Revolo Biotherapeutics, Slough, United Kingdom, 5Revolo Biotherapeutics, Exeter, United Kingdom, 6University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: In Rheumatoid arthritis (RA), osteoclasts derived from CD14+ Monocytes are associated with a risk of progressive bone and joint destruction, which fundamentally impacts quality-of-life.…
  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology